Publications by authors named "Rose O Masaba"
Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy: Observational Cohort From 9 African Countries.
J Acquir Immune Defic Syndr
November 2024
Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries.
Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe.
Methods: From January 2019 to December 2022, we collected data from a cohort of children, adolescents, and young people receiving third-line ART from 9 sub-Saharan African countries.
Article Synopsis
- * A study analyzed data from 6,649 AHD clients out of 19,427 HIV-positive individuals across eight facilities, focusing on demographics, clinical stages, and care settings, revealing that 56% of the participants were female and the median age was 46.0 years.
- * The results indicated significant differences between treatment-naïve and treatment-experienced clients, with ART-experienced patients more likely to visit primary care facilities and present with advanced clinical stages, and they also experienced higher mortality or loss to follow-up rates
Article Synopsis
- Viral suppression among children and adolescents on antiretroviral therapy in Kenya was found to be inadequate, prompting the implementation of a standardized enhanced adherence counseling (SEAC) package aimed at improving outcomes in those suspected of treatment failure.
- The SEAC package included training for providers, mentorship for peer educators, and individualized care, and it resulted in a significant reduction in time to initiate counseling and complete sessions post-implementation.
- The study showed a notable increase in the percentage of clients completing the recommended counseling sessions, with 88.4% post-SEAC compared to only 61.1% pre-SEAC, demonstrating the effectiveness of the intervention.
Background: Health benefits and survival of an exclusively breast-fed infant is dependent on the mother's health; thus, the need for antiretroviral (ARV) intervention for prevention of mother-to-child transmission (PMTCT). Achieving maternal health benefits from these regimens requires adherence to the treatments and close monitoring. We evaluated virologic, immunologic responses, and adherence among women receiving maternal triple ARV prophylaxis consisting of lamivudine/zidovudine and nevirapine or nelfinavir in the Kisumu Breastfeeding Study.
View Article and Find Full Text PDFIn the Kisumu Breastfeeding Study (KiBS), prevention of mother-to-child HIV transmission study, highly active antiretroviral therapy (HAART) is provided from 34 weeks gestation, through delivery to six months postpartum. The study recommends that women practice exclusive breastfeeding for six months, then wean abruptly. We sought to explore factors such as, education, family support, cultural norms, and sources of information about perinatal HIV transmission, which may influence a mother's decision to comply or not comply with the study's recommendation to stop breastfeeding when HAART is discontinued.
View Article and Find Full Text PDF